| Autor: |
Chen AJ; Alice J. Chen (alicejc@usc.edu), University of Southern California, Los Angeles, California., Kaiser KM; Katrina M. Kaiser, Caltrans, Los Angeles, California., Gascue L; Laura Gascue, UnitedHealthcare, Los Angeles, California., Manetas MA; Maria-Alice Manetas, University of Southern California., Van Nuys K; Karen Van Nuys, University of Southern California. |
| Jazyk: |
angličtina |
| Zdroj: |
Health affairs (Project Hope) [Health Aff (Millwood)] 2023 Jun; Vol. 42 (6), pp. 779-784. |
| DOI: |
10.1377/hlthaff.2022.01448 |
| Abstrakt: |
Using Medicare claims, we documented US prescribing patterns for originator biologic trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019. The first biosimilar captured a dominant share, but over time, average sales prices of all products declined, and later entrants became dominant in some states. Despite strong brand loyalty to the first biosimilar, competitive pressure increased with subsequent entrants. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
